Gruppo Lepetit S.p.a.

Merrell Dow Pharmaceuticals

Gruppa Lepetit S.p.a.

Ernesto Riva

Maurizio Denaro

Giovanni Cassani

Enrico Selva

Francesco Parenti

Pietro Ferrari

Pier Giorgio Righetti

Khalid Islam

Graziella Beretta

Franco Maria Spreafico

Luigi Franco Zerilli

Alessandra Maria Bossi

Purification of dalbaheptide antibiotics by isoelectric focusing

The present invention is directed to a new antibiotic denominated antibiotic GE1655 complex, its factors antibiotic GE1655 factor A, antibiotic GE1655 factor B, and antibiotic GE1655 factor C, the pharmaceutical acceptable salts thereof, the pharmaceutical compositions thereof, and their use as medicaments against bacteria and fungi, particularly for the treatment of fungal infections in animals and human beings.

Antibiotic GE1655 complex and its factors A, B, and C

A novel antibiotic, A 42867, is prepared by cultivating the strain Nocardia sp. ATCC 53492, or an antibiotic A 42867-producing mutant or variant thereof, under submerged aerobic conditions in the presence of assimilable sources of carbon, nitrogen and inorganic salts. The antibiotic and its addition salts are useful in the treatment of infectious diseases and as growth promotant agents.

Nocardia sp. ATCC 53492, or an antibiotic A 42867 producing mutant or

The present invention is directed to a new antibiotic substance denominated antibiotic A 42867 pseudoaglycon, a pharmaceutically acceptable salt thereof, a process for its preparation from antibiotic A 42867 and pharmaceutical compositions containing the new substance of the invention.

Antibiotic a 42867 derivative

The present invention concerns new antibiotic substances denominated antibiotic A 40926 N-acylaminoglucuronyl aglycon complex AB, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor A, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.0, antibiotic A 40926 N-acylaminoglucuronyl aglycon factor B.sub.1, antibiotic A 40926 aglycon and the addition salts thereof, a process for their preparation starting from antibiotic A 40926 complex or a factor thereof, and their use in the treatment of infectious diseases involving microorganisms susceptible to them.

Antibiotic A 40926 N-acylaminoglucuronyl aglycons and antiobiotic A

Antibiotic A 42867 and the addition salts thereof

Growing community of inventors

Milan, Italy

Ernesto Riva